Literature DB >> 16186282

Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program.

.   

Abstract

OBJECTIVE: Individuals with impaired glucose tolerance (IGT) appear to be at increased risk for cardiovascular disease (CVD) due at least in part to an increased prevalence of risk factors. We evaluated lipid, lipoprotein, C-reactive protein (CRP), fibrinogen, and tissue plasminogen activator (tPA) levels at study entry in the largest multiethnic cohort of participants with IGT described, namely in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: Measurements were performed at the baseline visit of 3,819 randomized participants of the DPP. Among 3,622 participants who were not taking lipid-lowering medicines, cardiovascular risk factors were analyzed in relation to demographic, anthropometric, and metabolic measures. Major determinants of risk factors were assessed in multivariate analysis.
RESULTS: Over 40% of participants had elevated triglyceride, LDL cholesterol, and CRP levels and reduced HDL cholesterol levels. Men had higher triglyceride and tPA and lower HDL cholesterol concentrations and smaller LDL particle size than women, whereas women had higher CRP and fibrinogen levels. African Americans had less dyslipidemia but higher fibrinogen levels, and Asian Americans had lower CRP and fibrinogen levels than Caucasians and Hispanics. The surrogate measure of insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR]) had the strongest association with HDL cholesterol, triglyceride, and tPA levels and LDL particle size. BMI had the greatest influence on CRP and fibrinogen levels. Using median splits of indexes of insulin resistance and insulin secretion (insulin-to-glucose ratio), participants with greater insulin resistance had a more adverse CVD risk-factor profile, whereas insulin secretion had little influence on risk factors.
CONCLUSIONS: The pattern of CVD risk factors in participants with IGT in the DPP exhibits substantial heterogeneity and is significantly influenced by race, sex, and age, as well as by obesity, glucose, and insulin measures. The degree of insulin resistance, as reflected by HOMA-IR, showed the greatest association with the cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186282      PMCID: PMC1404506          DOI: 10.2337/diacare.28.10.2472

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  44 in total

1.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

Authors:  S M Haffner; L Mykkänen; A Festa; J P Burke; M P Stern
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

2.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

Authors:  S M Haffner; M P Stern; H P Hazuda; B D Mitchell; J K Patterson
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

5.  Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women.

Authors:  P Vague; I Juhan-Vague; V Chabert; M C Alessi; C Atlan
Journal:  Metabolism       Date:  1989-09       Impact factor: 8.694

6.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; L Mykkänen; R P Tracy; D J Zaccaro; C N Hales; S M Haffner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

7.  Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study.

Authors:  C M Burchfiel; R F Hamman; J A Marshall; J Baxter; L B Kahn; J J Amirani
Journal:  Am J Epidemiol       Date:  1990-01       Impact factor: 4.897

8.  Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population.

Authors:  C C Cowie; B V Howard; M I Harris
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

9.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

10.  Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Carlos J Crespo; Ellen Smit; Anastacia Snelling; Christopher T Sempos; Ross E Andersen
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

View more
  19 in total

1.  Sex Hormones and Measures of Kidney Function in the Diabetes Prevention Program Outcomes Study.

Authors:  Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

2.  Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes.

Authors:  C Kim; C A Christophi; R B Goldberg; L Perreault; D Dabelea; S M Marcovina; X Pi-Sunyer; E Barrett-Connor
Journal:  Diabet Med       Date:  2015-05-29       Impact factor: 4.359

3.  Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

Authors:  H Florez; M G Temprosa; T J Orchard; K J Mather; S M Marcovina; E Barrett-Connor; E Horton; C Saudek; X F Pi-Sunyer; R E Ratner; R B Goldberg
Journal:  Diabetes Obes Metab       Date:  2013-10-29       Impact factor: 6.577

4.  Menopause and risk of diabetes in the Diabetes Prevention Program.

Authors:  Catherine Kim; Sharon L Edelstein; Jill P Crandall; Dana Dabelea; Abbas E Kitabchi; Richard F Hamman; Maria G Montez; Leigh Perreault; Mary A Foulkes; Elizabeth Barrett-Connor
Journal:  Menopause       Date:  2011-08       Impact factor: 2.953

Review 5.  Metabolic syndrome in blacks: are the criteria right?

Authors:  Kwame Osei
Journal:  Curr Diab Rep       Date:  2010-06       Impact factor: 4.810

6.  Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Marinella Temprosa; Lisa Mele; Trevor Orchard; Kieren Mather; George Bray; Edward Horton; Abbas Kitabchi; Jonathan Krakoff; Santica Marcovina; Leigh Perreault; Neil White
Journal:  Metabolism       Date:  2015-12-02       Impact factor: 8.694

Review 7.  Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Kieren Mather
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

8.  Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.

Authors:  Ronald B Goldberg; John R Guyton; Theodore Mazzone; Ruth S Weinstock; Adam B Polis; Diane Tipping; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Diabetes Care       Date:  2010-02-11       Impact factor: 19.112

9.  Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study.

Authors:  Fumiaki Imamura; Kenneth J Mukamal; James B Meigs; José A Luchsinger; Joachim H Ix; David S Siscovick; Dariush Mozaffarian
Journal:  Am J Epidemiol       Date:  2013-05-24       Impact factor: 4.897

10.  Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program.

Authors:  Mary de Groot; David Marrero; Lisa Mele; Todd Doyle; Frank Schwartz; Kieren J Mather; Ronald Goldberg; David W Price; Yong Ma; William C Knowler
Journal:  Psychosom Med       Date:  2018 Feb/Mar       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.